Cynthia Seidel-Dugan
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Cynthia Seidel-Dugan
Werewolf Therapeutics, Inc. reported in an 8-K filed March 7, 2024 that Cynthia Seidel-Dugan retired as Chief Scientific Officer, effective March 29, 2024. The proxy statement of Werewolf Therapeutics, Inc. reports total compensation of $1,210,878 for Cynthia Seidel-Dugan in fiscal 2022, including a base salary of $416,000. Disclosed compensation is on record for 2 fiscal years.
“On March 3, 2024, Cynthia Seidel-Dugan, Ph.D., notified the Company of her intent to retire from her position as Chief Scientific Officer of the Company, effective as of March 29, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Werewolf Therapeutics, Inc. (HOWL)
Proxy statement
Start not stated–2024-03-29
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Werewolf Therapeutics, Inc. (HOWL) | Chief Scientific Officer | $416,000 | $1,210,878 |
| 2021 | Werewolf Therapeutics, Inc. (HOWL) | Chief Scientific Officer | $387,016 | $1,186,721 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.